Federal Circuit Upholds Pfizer Patent, Blocks Generic Xalatan
Pfizer Inc.'s glaucoma drug Xalatan is off limits to generics manufacturer Par Pharmaceutical Inc., following a decision in Pfizer's favor by the U.S. Court of Appeals for the Federal Circuit....To view the full article, register now.
Already a subscriber? Click here to view full article